Although only exon 17 mutations in KIT have been established as a poor prognostic factor in RUNX1::RUNX1T1-AML (30), other KIT activating mutations may also serve as potential molecular targets for AML treatment, particularly in relapsed cases (31). The gene discussed is RUNX1; the disease is acute myeloid leukemia.